skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Cognitive function in treated HIV patients

Review

(1422) Views  (652) Full article downloads

Authors: Valerio Tozzi, Pietro Balestra, Raffaella Libertone, et al

Published Date November 2010 Volume 2010:2 Pages 95 - 113
DOI: http://dx.doi.org/10.2147/NBHIV.S13936

Valerio Tozzi, Pietro Balestra, Raffaella Libertone, Andrea Antinori
Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy

Abstract: Although highly active antiretroviral therapy (HAART) has reduced the incidence of HIV-associated dementia, the overall prevalence of HIV-associated neurocognitive disorders (HAND) has increased. Since treatment and prevention of HAND are becoming an increasing concern, management strategies for cognitive impairment in patients living with HIV are expected to play an important role in the near future. This review summarizes the existing literature on studies investigating cognitive functions in patients receiving antiretroviral (ARV) treatment. Most studies indicate that HAART use results in improvement of neurocognitive functions, yet milder forms of HAND are not only prevalent, but also incident in patients with persistently undetectable plasma HIV RNA. We performed a systematic review on all studies performed in patients receiving ARV treatment that included neurocognitive evaluations as study end points. Thirty-six studies were examined. Study methodology varied from cross-sectional to double-blind, randomized, controlled designs. Aside from historic zidovudine monotherapy trials, in most studies, ARV schemes varied considerably, and in some cases, ARV regimens were not reported in detail. Only a few articles included virological studies on cerebrospinal fluid. Study duration was <2 years in most cases. Differences in study design and presence of study limitations may account for difficulties in understanding the impact of HAART on cognition and in evaluating the effect of an individual agent or ARV regimen on cognitive functioning. The aim of the present article is to provide HIV clinicians with a comprehensive review of recent achievements and future prospects for ARV treatment and prevention of cognitive dysfunctions in HIV-infected patients.

Keywords: highly active antiretroviral therapy, neurocognitive disorders, HIV dementia, central nervous system






Readers of this article also read:

Variable cognitive benefits in HAART-treated patients: are aging and low cholesterol linked?
A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease
Depression care and prevalence in HIV-positive individuals
Impact of HIV infection and alcohol on cognition: a review
Development of neurocognitive disorders in HIV/AIDS
Depression, alcohol abuse, and disclosure of HIV serostatus among rural HIV-positive individuals in western Uganda
A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers
Cognitive reserve masks neurobehavioral expression of human immunodeficiency virus-associated neurological disorder in older patients
Immune activation and neuropsychiatric symptoms in human immunodeficiency virus type 1 infection